<DOC>
	<DOCNO>NCT02912702</DOCNO>
	<brief_summary>This study aim investigate efficacy safety Pegaspargase together liposomal doxorubicin , etoposide high dose methylprednisolone ( L-DEP ) initial treatment Epstein Barr virus-induced hemophagocytic lymphohistiocytosis .</brief_summary>
	<brief_title>L-DEP Initial Treatment EBV-HLH</brief_title>
	<detailed_description />
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients older 14 year age 2 . Diagnosed EBVHemophagocytic Lymphohistiocytosis ( HLH ) 3 . Patients receive treatment HLH 4 . Informed consent 1 . Heart function grade II ( NYHA ) 2 . Accumulated dose doxorubicin 300mg/m2 epirubicin 450mg/m2 3 . Pregnancy lactate Women 4 . Allergic Pegaspargase , doxorubicin etoposide 5 . Active bleed internal organ 6. uncontrollable infection 7. history acute chronic pancreatitis 8 . Participate clinical research time</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pegaspargase</keyword>
	<keyword>hemophagocytic lymphohistiocytosis</keyword>
	<keyword>Epstein Barr virus</keyword>
	<keyword>initial treatment</keyword>
</DOC>